# Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC

Source: https://onco.cc/trials/nct07447570/  
OnCo record `nct07447570` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Iparomlimab and tuvonralimab in Head and neck squamous cell carcinoma, run by Second Affiliated Hospital, Zhejiang University, School of Medicine, now recruiting.

## Summary

Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC is a phase 2 interventional study registered as NCT07447570 by Second Affiliated Hospital, Zhejiang University, School of Medicine, with 27 participants planned, started 2025-10-15 and due to reach its primary completion in 2027-12-31. Interventions recorded: Iparomlimab and Tuvonralimab injection, Hypofractionated Radiotherapy, Chemotherapy. Conditions recorded: Head and Neck Cancer, Radiotherapy, Anti-PD-1/CTLA-4 Antibody.

Linked to the drug Iparomlimab and tuvonralimab because the registry names it among its interventions and Head and neck squamous cell carcinoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07447570
- Phase: 2
- Setting: Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: a Multicenter, Single-arm, Phase II Clinical Study
- Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
- Enrolled: 27

## Sources

- ClinicalTrials.gov NCT07447570: https://clinicaltrials.gov/study/NCT07447570

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [Iparomlimab and tuvonralimab](https://onco.cc/drugs/iparomlimab-tuvonralimab/)

---
JSON: https://onco.cc/api/v1/entities/nct07447570.json